CAR+ extracellular vesicles predict ICANS in patients with B cell lymphomas treated with CD19-directed CAR T cells

被引：2

作者：

Storci, Gianluca ^{[1
]}

De Felice, Francesco ^{[1
,2
]}

Ricci, Francesca ^{[1
]}

Santi, Spartaco ^{[3
,4
]}

Messelodi, Daria ^{[1
]}

Bertuccio, Salvatore Nicola ^{[1
]}

Laprovitera, Noemi ^{[1
]}

Dicataldo, Michele ^{[1
,2
]}

Rossini, Lucrezia ^{[2
]}

De Matteis, Serena ^{[1
]}

Casadei, Beatrice ^{[1
]}

Vaglio, Francesca ^{[1
]}

Ursi, Margherita ^{[1
,2
]}

Barbato, Francesco ^{[1
,2
]}

Roberto, Marcello ^{[1
,2
]}

Guarino, Maria ^{[1
]}

Asioli, Gian Maria ^{[1
]}

Arpinati, Mario ^{[1
]}

Cortelli, Pietro ^{[5
,6
]}

Maffini, Enrico ^{[1
]}

Tomassini, Enrica ^{[1
]}

Tassoni, Marta ^{[2
]}

Cavallo, Carola ^{[7
]}

Iannotta, Francesco ^{[1
]}

Naddeo, Maria ^{[1
,2
]}

Tazzari, Pier Luigi ^{[1
]}

Dan, Elisa ^{[1
]}

Pellegrini, Cinzia ^{[1
]}

Guadagnuolo, Serafina ^{[1
]}

Carella, Matteo ^{[1
,2
]}

Sinigaglia, Barbara ^{[1
]}

Pirazzini, Chiara ^{[2
]}

Severi, Caterina ^{[8
]}

Garagnani, Paolo ^{[1
,2
]}

Kwiatkowska, Katarzyna Malgorzata ^{[2
]}

Ferracin, Manuela ^{[1
,2
]}

Zinzani, Pier Luigi ^{[2
,9
]}

Bonafe, Massimiliano ^{[1
,2
]}

Bonifazi, Francesca ^{[1
]}

机构：

[1] IRCCS, Azienda Osped Univ Bologna, Bologna, Italy

[2] Univ Bologna, Dipartimento Sci Med & Chirurg, Bologna, Italy

[3] IRCCS, Ist Ortoped Rizzoli, Bologna, Italy

[4] Natl Res Council Italy, Inst Mol Genet, Bologna, Italy

[5] Univ Bologna, Bellaria Hosp, Dept Biomed & Neuromotor Sci, Bologna, Italy

[6] IRCCS, Bellaria Hosp, Inst Neurol Sci Bologna, Bologna, Italy

[7] IRCCS, Res & Innovat Technol Dept, Ist Ortoped Rizzoli, Lab Ramses, Bologna, Italy

[8] Abbelight, Cachan, France

[9] IRCCS, Azienda Osped Univ Bologna, Ist Ematol Seragnoli, Bologna, Italy

来源：

JOURNAL OF CLINICAL INVESTIGATION | 2024年 / 134卷 / 14期

关键词：

THERAPY; NEUROTOXICITY; MANAGEMENT; CHILDREN; ADULTS; BLOOD;

D O I：

10.1172/JCI173096

中图分类号：

R-3 [医学研究方法]; R3 [基础医学];

学科分类号：

1001 ;

摘要：

BACKGROUND. Predicting immune effector cell-associated neurotoxicity syndrome (ICANS) in patients infused with CAR T cells is still a conundrum. This complication, thought to be consequent to CAR T cell activation, arises a few days after infusion, when circulating CAR T cells are scarce and specific CAR T cell-derived biomarkers are lacking. METHODS. CAR + extracellular vesicle (CAR + EV) release was assessed in human CD19.CAR T cells cocultured with CD19 + target cells. A prospective cohort of 100 patients with B cell lymphoma infused with approved CD19.CAR T cell products was assessed for plasma CAR + EVs as biomarkers of in vivo CD19.CAR T cell activation. Human induced pluripotent stem cell- derived (iPSC-derived) neural cells were used as a model for CAR + EV-induced neurotoxicity. RESULTS. In vitro release of CAR + EVs occurs within 1 hour after target engagement. Plasma CAR + EVs are detectable 1 hour after infusion. A concentration greater than 132.8 CAR + EVs/ mu L at hour +1 or greater than 224.5 CAR + EVs/ mu L at day +1 predicted ICANS in advance of 4 days, with a sensitivity and a specificity outperforming other ICANS predictors. ENO2 + nanoparticles were released by iPSC-derived neural cells upon CAR + EV exposure and were increased in plasma of patients with ICANS. CONCLUSION. Plasma CAR + EVs are an immediate signal of CD19.CAR T cell activation, are suitable predictors of neurotoxicity, and may be involved in ICANS pathogenesis.

引用

页数：17

共 50 条

[31] CD19 CAR-T expressing PD-1/CD28 chimeric switch receptor as a salvage therapy for DLBCL patients treated with different CD19-directed CAR T-cell therapies
Liang, Yun
Liu, Hui
Lu, Zheming
Lei, Wen
Zhang, Chaoting
Li, Ping
Liang, Aibin
Young, Ken H.
Qian, Wenbin
JOURNAL OF HEMATOLOGY & ONCOLOGY, 2021, 14 (01)
[32] CD19 CAR-T expressing PD-1/CD28 chimeric switch receptor as a salvage therapy for DLBCL patients treated with different CD19-directed CAR T-cell therapies
Yun Liang
Hui Liu
Zheming Lu
Wen Lei
Chaoting Zhang
Ping Li
Aibin Liang
Ken H. Young
Wenbin Qian
Journal of Hematology & Oncology, 14
[33] Treatment of adult ALL patients with third-generation CD19-directed CAR T cells: results of a pivotal trial
Schubert, Maria-Luisa
Schmitt, Anita
Hueckelhoven-Krauss, Angela
Neuber, Brigitte
Kunz, Alexander
Waldhoff, Philip
Vonficht, Dominik
Yousefian, Schayan
Jopp-Saile, Lea
Wang, Lei
Korell, Felix
Keib, Anna
Michels, Birgit
Haas, Dominik
Sauer, Tim
Derigs, Patrick
Kulozik, Andreas
Kunz, Joachim
Pavel, Petra
Laier, Sascha
Wuchter, Patrick
Schmier, Johann
Bug, Gesine
Lang, Fabian
Goekbuget, Nicola
Casper, Jochen
Goerner, Martin
Finke, Juergen
Neubauer, Andreas
Ringhoffer, Mark
Wolleschak, Denise
Brueggemann, Monika
Haas, Simon
Ho, Anthony D.
Mueller-Tidow, Carsten
Dreger, Peter
Schmitt, Michael
JOURNAL OF HEMATOLOGY & ONCOLOGY, 2023, 16 (01)
[34] Treatment of adult ALL patients with third-generation CD19-directed CAR T cells: results of a pivotal trial
Maria-Luisa Schubert
Anita Schmitt
Angela Hückelhoven-Krauss
Brigitte Neuber
Alexander Kunz
Philip Waldhoff
Dominik Vonficht
Schayan Yousefian
Lea Jopp-Saile
Lei Wang
Felix Korell
Anna Keib
Birgit Michels
Dominik Haas
Tim Sauer
Patrick Derigs
Andreas Kulozik
Joachim Kunz
Petra Pavel
Sascha Laier
Patrick Wuchter
Johann Schmier
Gesine Bug
Fabian Lang
Nicola Gökbuget
Jochen Casper
Martin Görner
Jürgen Finke
Andreas Neubauer
Mark Ringhoffer
Denise Wolleschak
Monika Brüggemann
Simon Haas
Anthony D. Ho
Carsten Müller-Tidow
Peter Dreger
Michael Schmitt
Journal of Hematology & Oncology, 16
[35] Clinicopathologic Findings in Fatal Neurotoxicity After Adoptive Immunotherapy With CD19-Directed CAR T-Cells
Karschnia, Philipp
Struebing, Felix
Teske, Nico
Blumenberg, Viktoria
Buecklein, Veit L.
Schmidt, Christian
Schoeberl, Florian
Dimitriadis, Konstantinos
Forbrig, Robert
Stemmler, Hans-Joachim
Tonn, Joerg-Christian
Von Bergwelt-Baildon, Michael
Subklewe, Marion
von Baumgarten, Louisa
HEMASPHERE, 2021, 5 (03): : E533
[36] Myeloid Cell Phenotype in the Setting of CD19-Directed CAR T-Cell Therapy: Relationship to Relapse and Toxicity
Lust, Hannah
Miller, Stephen
Karmali, Reem
Chaudhury, Sonali
BLOOD, 2022, 140 : 4508 - 4509
[37] Recombinant CD19 Glycomutant Accurately and Reproducibly Detects CD19-Directed CAR-T Cells By Flow Cytometry
Kirchmeier, Delaney R.
Sheih, Alyssa
Fiorenza, Salvatore
Hirayama, Alexandre V.
Chou, Cassie
Kimble, Erik
Gauthier, Jordan
Williams, Alison
Price, Jason
Correnti, Colin
Turtle, Cameron J.
BLOOD, 2021, 138
[38] Use of CD19-directed CAR T-Cell Therapy in an Infant With Refractory Acute Lymphoblastic Leukemia
Breese, Erin H.
Krupski, Christa
Nelson, Adam S.
Perentesis, John P.
Phillips, Christine L.
JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, 2021, 43 (04) : 152 - 154
[39] Real-World Treatment Patterns After CD19-Directed CAR T Cell Therapy Among Patients with Diffuse Large B Cell Lymphoma
Jalbert, Jessica J.
Wu, Ning
Chen, Chieh-, I
Ambati, Srikanth
Ge, Wenzhen
Arnason, Jon E.
ADVANCES IN THERAPY, 2022, 39 (06) : 2630 - 2640
[40] CD19 COMPLETE OR PARTIAL LOSS IS A MAJOR MECHANISM OF RELAPSE IN DLBCL PATIENTS TREATED WITH CD19-DIRECTED CAR-T CELLS: EXPERIENCE OF PERUGIA HEMATOLOGY CENTER
Perriello, V. M.
Falini, L.
Ruggeri, L.
Venanzi, A.
Zei, T.
Iacucci-Ostini, R.
Pierini, A.
Ballanti, S.
Tiacci, E.
Falini, B.
HAEMATOLOGICA, 2022, 107 : 93 - 93

← 1 2 3 4 5 →